Healthcare / Drug Manufacturers - Specialty & GenericKSE
$123000.00
-3400.00 (-2.60%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-92.2B · quality 36.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
45/100
C
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.42T
P/E
7.2x
↓EV/EBITDA
8.1x
↓ROE
19.5%
↑Gross Margin
52.4%
↑Debt/Equity
0.82
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
-5.9%
FCF / Net income
-0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.57T · net income $195.86B · FCF $-92.16B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1570.89B | $1570.89B | $1422.68B | $1375.33B | $1280.09B |
| Net Income | $195.86B | $195.86B | $24.73B | $121.74B | $42.24B |
| EBITDA | $255.38B | $255.38B | $112.52B | $179.40B | $86.43B |
| EPS | 17022.00 | 17022.00 | 2150.00 | 10656.00 | 3816.00 |
| Gross Margin | 52.4% | 52.4% | 51.6% | 50.0% | 49.9% |
| Operating Margin | 12.5% | 12.5% | 10.4% | 8.9% | 7.5% |
| Net Margin | 12.5% | 12.5% | 1.7% | 8.9% | 3.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.82 | 0.82 | 0.82 | 0.58 | 0.73 |
| Current Ratio | 1.12 | 1.12 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-92.16B | $-92.16B | $-177.51B | $-20.16B | $4.91B |
| Returns | |||||
| ROE | 19.5% | 19.5% | 3.1% | 15.9% | 6.9% |
| Valuation | |||||
| P/E | 7.23 | 7.23 | 59.16 | 10.68 | 39.83 |
| EV/EBITDA | 8.13 | 8.13 | 17.86 | 9.09 | 23.44 |
| P/B | 1.41 | 1.41 | 1.84 | 1.69 | 2.77 |
| Growth & Yield | |||||
| Revenue Growth | 10.4% | 10.4% | 3.4% | 7.4% | — |
| EPS Growth | 691.7% | 691.7% | -79.8% | 179.2% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-13.8%
EPS terminal req.
$10914.20
Spread vs growth
705.5%
5Y implied EPS CAGR
-4.9%
EPS terminal req.
$13206.18
Spread vs growth
696.7%
10Y implied EPS CAGR
2.3%
EPS terminal req.
$21268.69
Spread vs growth
689.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-7.8%
Start / end P/E
64.5x → 7.5x
EPS bridge
2150.00 → 17022.00
Residual
-611.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.